A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) Conducted Globally
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Lumateperone (Primary)
- Indications Bipolar depression
- Focus Therapeutic Use
- Sponsors Intra-Cellular Therapies
- 08 Nov 2017 Status changed from not yet recruiting to recruiting.
- 12 Aug 2017 New trial record
- 11 Aug 2017 Status changed from planning to not yet recruiting.